More Than Three Years of Hepatic Recurrence-Free Survival After Radiofrequency Ablation for Hepatic Metastasis From Triple-Negative Breast Cancer

The prognosis of triple-negative breast cancer (TNBC) with hepatic metastasis is generally poor. Here, we report the case of a 70-year-old woman with TNBC whose hepatic metastasis did not recur for more than three years after radiofrequency ablation (RFA). During this period, the patient received chemotherapies with relatively mild side effects, such as eribulin mesylate and gemcitabine, maintaining a good quality of life. Although PARP inhibitors and immune checkpoint inhibitors are now available for TNBC, many cases are not eligible for these treatments due to the absence of specific target molecules. RFA may be a useful option in selected cases of hepatic metastasis from TNBC.